Admaius Capital Partners, a leading Africa-focused private equity firm, has entered into a strategic partnership with Triquera, the majority shareholder of Minapharm—a pioneering biopharmaceutical company operating across the Middle East, Africa, and Europe. This collaboration follows Admaius’ investment in Triquera and marks a significant milestone in advancing healthcare innovation and accessibility across underserved markets.
Minapharm has built a world-class biopharmaceutical platform over the past two decades, integrating cutting-edge research and development with comprehensive manufacturing capabilities. Operating from facilities in Cairo and Berlin, Minapharm specializes in the production of complex genetically engineered therapeutic proteins, viral vectors, and advanced small molecule formulations. It currently houses the largest biological drug substance and drug product facilities in the Middle East and Africa.
Through its international subsidiaries, Minapharm licenses proprietary technologies in monoclonal antibodies, vaccines, and cell and gene therapies. These technologies have been incorporated into FDA-approved products, demonstrating their global clinical relevance and impact.
The partnership between Triquera and Admaius aims to accelerate the development and distribution of advanced biologics, particularly recombinant proteins, by investing in innovation and expanding access across Africa and the Middle East. In addition, the collaboration will pursue strategic acquisitions of global contract development and manufacturing organizations (CDMOs) to support Minapharm’s continued growth in the biotech sector.
This alliance reflects a shared commitment to healthcare equity and aligns with Admaius’ broader mission to support purpose-driven businesses and visionary leadership teams across high-impact sectors in Africa.
- Zilla Capital served as the exclusive financial advisor to Triquera and its shareholders.
- Matouk Bassiouny provided legal counsel to Triquera and its shareholders.
- White & Case LLP acted as legal counsel to Admaius Capital Partners.
- Arthur D. Little served as Admaius’ commercial advisor.
Dr. Wafik Bardissi, Chairman and CEO of Minapharm, stated:
This partnership marks a pivotal moment in Minapharm’s journey as we expand our leadership in biotherapeutics and proprietary platform technologies. Admaius brings not only capital but strategic alignment and ambition that matches our own. Together, we are advancing regional self-sufficiency and global reach.
Marlon Chigwende, Managing Partner at Admaius, commented:
This is a landmark transaction. The founding families have built a unique asset that spans Africa and Europe, combining scale, innovation, and impact to combat serious diseases. We are proud to partner with Triquera, Dr. Wafik, and Dr. Shaheer to further internationalize and grow the business
Ahmed Rady, Managing Director at Admaius, added:
We invest in exceptional management teams, and the team behind Minapharm is as impressive as the science and technology they’ve developed. This partnership is about scaling a homegrown champion with global capabilities.
Dr. Shaheer Bardissi, Co-CEO of Minapharm, concluded:
Our collaboration with Admaius will accelerate Minapharm’s mission to deliver affordable, cutting-edge therapies while advancing global scientific frontiers in immunotherapy and advanced medicinal products.
